Quantessence Capital’s Arcellx ACLX Stock Holding History

Quantessence Capital’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,750	Closed	-$313K	–	174
2025 Q2	$313K	Buy	+4,750	New	+$296K	0.09%	140

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Quantessence Capital's ACLX Position: Q3 2025 in Review

Quantessence Capital sold out of Arcellx (ACLX) in Q3 2025, closing a stake of 4,750 shares — an estimated $313K sold.

Quantessence Capital first reported a position in ACLX in Q2 2025 and held it in 1 quarter. The position peaked at $313K in Q2 2025. 209 funds tracked by Wall St. Rank hold ACLX as of Q3 2025.

Quantessence Capital reported no remaining Arcellx position as of Q3 2025 after selling out during the quarter.
Quantessence Capital sold 4,750 Arcellx shares in Q3 2025, an estimated $313K.
Quantessence Capital first reported a position in Arcellx in Q2 2025 and held it in 1 quarter.
Quantessence Capital's Arcellx position peaked at $313K in Q2 2025.
209 funds tracked by Wall St. Rank held Arcellx as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.